Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Regeneron has expanded its research alliance with CytomX Therapeutics, paying $37 million to work on conditionally active bispecifics against two targets and secure options on more programs. The expansion swells the potential value of the deal to about $4 billion.